Zacks Investment Research
24 Jun 2026, 12:37 UTC · 2h ago
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
24 Jun 2026, 12:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Aquestive Therapeutics expects to resubmit its new drug application (NDA) for its lead product candidate, Anaphylm, in the third quarter of 2026. — The resubmission of a lead product candidate's NDA is a primary catalyst for regulatory approval and future commercial revenue.
+0.40Aquestive Therapeutics is projected to report quarterly revenues of $12.26 million, a 22.6% increase year-over-year. — Double-digit revenue growth indicates positive commercial momentum for the company's existing offerings.
+0.20The company is expected to report a quarterly loss of $0.10 per share, representing a 28.6% year-over-year increase in loss. — Increasing quarterly losses can weigh on investor sentiment despite revenue growth.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
The consensus EPS estimate for Aquestive Therapeutics has remained unchanged over the last 30 days. — A lack of positive earnings revisions often suggests a ceiling on near-term price appreciation.
-0.10Which stocks this story touches
Shares rallied 6.6% due to growing investor confidence in the commercial prospects of its lead product candidate, Anaphylm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
